insulin
Sanofi abandons MannKind’s failed inhalable insulin
January 6, 2016Manufacturing and Production, Research and Development, Sales and Marketing Afrezza, Mannkind, Sanofi, insulin
Sanofi is to exit a licensing and co-marketing deal with MannKind for the inhalable insulin Afrezza, after disappointing sales figures …
FDA approves Lilly/Boehringer Lantus biosimilar
December 17, 2015Medical Communications, Sales and Marketing Basaglar, Boehringer Ingelheim, Eli Lilly, Lantus, Sanofi, abasaglar, biosimilar, diabetes, insulin, lilly
The FDA has approved Eli Lilly and Boehringer Ingelheim’s long-acting insulin Basaglar (insulin glargine injection – a biosimilar to rival Sanofi’s …
Novo Nordisk posts strong nine-month results
October 29, 2015Sales and Marketing Novo Nordisk, insulin
Novo Nordisk has exceeded market expectations in its nine-month financial results, reporting a 51% increase in operating profit and 33% …
FDA approves Novo Nordisk’s diabetes drugs
September 28, 2015Sales and Marketing FDA, Novo Nordisk, Ryzodeg, Tresiba, diabetes, insulin
The FDA has approved two Novo Nordisk drugs, Tresiba and Ryzodeg, for the treatment of type 2 diabetes in adults.The …
Novo Nordisk abandons Victoza submission after mixed T1D results
August 26, 2015Research and Development Novo Nordisk, Victoza, diabetes, insulin
Novo Nordisk has been forced to scrap plans to expand its licence for Victoza to include adults with type 1 …
Sanofi launches new insulin Toujeo in the UK
August 4, 2015Manufacturing and Production, Sales and Marketing Lantus, Sanofi, biosimilars, diabetes, hypoglycaemia, insulin, toujeo
Sanofi’s new insulin Toujeo is now available for clinicians to prescribe in the UK. The French firm is looking to …
Mixed Phase 3 results for Sanofi and UCB
July 29, 2015Research and Development LixiLan, Sanofi, UCB, clinical trials, epratuzumab, insulin, insulin glargine, phase III
Two drugs that pharma companies are pinning hopes on for future success have had mixed outcomes in key late-stage clinical …
Novo Nordisk opens insulin plant in Russia
April 10, 2015Manufacturing and Production, Sales and Marketing Novo Nordisk, Russia, diabetes, flexpen, insulin, kaluga, penfill
Denmark’s Novo Nordisk has opened a new manufacturing facility in Russia to produce more of its diabetes offerings in the …
NICE changes insulin advice in diabetes guidelines
December 12, 2014Sales and Marketing NHS, NICE, diabetes, health survey, insulin, type 1, type 2
NICE has changed its recommendations on type 1 diabetes in adults and children, and type 2 diabetes in children, to …
Sanofi signs $925 million inhaled insulin deal
August 13, 2014Sales and Marketing Afrezza, French, Sanofi, diabetes, fad, insulin
Sanofi could pay out as much as $925 million for global rights to the world’s only approved inhaled insulin just …
Insulin blockbusters targeted by biosimilar blitz
February 15, 2013Research and Development, Sales and Marketing Biocon, Humalog, Mylan, insulin
Mylan and Biocon are the latest companies to announce major new plans to develop and market biosimilars. The firms are …
New plant positions Lilly for changing insulin market
November 6, 2012Manufacturing and Production Boehringer, insulin, lilly
Eli Lilly has unveiled plans for a $140 million expansion of its insulin plant in Indianapolis as it starts to …
Novo confident on ultra-long acting insulin
December 8, 2011Sales and Marketing Novo Nordisk, diabetes, insulin
Novo Nordisk says a new combination of a long-acting insulin with a short-acting insulin helps patients maintain better control of …
No cancer link with Lantus, says Sanofi
December 7, 2011Sales and Marketing Cancer, Lantus, Sanofi, diabetes, insulin, safety
Sanofi has presented a new meta-analysis which suggests its insulin blockbuster Lantus does not raise the risk of cancer. A …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
